Product Description: Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Richardson D, et al. Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076). Gynecologic Oncology, 2022, 166: S48.
CAS Number: 2254118-43-7
Molecular Weight: N/A
Compound Purity: 98.77
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ADC Antibody